|
CA2708762A1
|
|
Formulation of insulinotropic peptide conjugates
|
|
US2009054332A1
|
|
Thombopoietin peptide conjugates
|
|
US2009088377A1
|
|
Cysteic acid derivatives of anti-viral peptides
|
|
US2009099074A1
|
|
Modulating food intake
|
|
US2008312415A1
|
|
Long lasting fusion peptide inhibitors for hiv infection
|
|
EP2114437A2
|
|
Modified corticotropin releasing factor peptides and uses thereof
|
|
CN101384623A
|
|
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
|
WO2007053946A1
|
|
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
|
AU2005218012A1
|
|
Long lasting growth hormone releasing factor derivatives
|
|
EP2100904A1
|
|
Solid phase for use in a method for the purification of albumin conjugates
|
|
US2005176643A1
|
|
Anti-obesity agents
|
|
AU2004261319A1
|
|
Long lasting insulin derivatives and methods thereof
|
|
US7741453B2
|
|
Long lasting fusion peptide inhibitors for HIV infection
|
|
EP1479691A1
|
|
Long lasting fusion peptide inhibitors for HIV infection
|
|
EP1752469A2
|
|
Long lasting fusion peptide inhibitors for HIV infection
|
|
EP1889639A2
|
|
Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
|
|
EP2110381A1
|
|
Long lasting fusion peptide inhibitors of viral infection
|
|
EP1199566A1
|
|
Methods of screening affinity marker libraries
|
|
CA2622018A1
|
|
Cellular and serum protein anchors and conjugates
|
